Analyst’s mean target price for Aurinia Pharmaceuticals Inc. He also pointed out that, of the 13 deaths, 11 occurred in Asia, a finding consistent with other LN studies and “probably related somewhat to patient management and severity of disease in this patient population”.
Advertisement
Thinly traded micro cap Aurinia Pharmaceuticals (NASDAQ:AUPH) perks up 17% premarket on modest volume in response to its announcement that its Phase 2b clinical trial, AURA-LV, assessing lead product candidate, Fast Track-tagged voclosporin, met its primary efficacy endpoint in patients with active lupus nephritis (LN), an inflammation of the kidney caused by the autoimmune disorder systemic lupus erythematosus (SLE).
According to a company statement, the drug reached its primary endpoint of achieving greater complete remission in the trial. Participants were randomized to receive one of two dosages of voclosporin (23.7 mg or 39.5 mg twice daily) or placebo.
Aurinia Pharmaceuticals Inc has the Market Capitalization of 0. The company reported the earnings of $-0.1/Share in the last quarter where the estimated EPS by analysts was $-0.11/share. Year to Date performance value (YTD perf) value is -26.72%. Current price level places the company’s stock about -59.69% from the 52-week high and 27.46% away from the 52-week low.
Net Loss: Net loss applicable to common stockholders was $6.5 million, or $0.33 per share, for the three months ended June 30, 2016, compared to net loss applicable to common stockholders of $6.9 million, or $0.36 per share, for the same period in 2015. One week ago, shares have been suggested as “BUY” from “1” brokerage firms and recommended as “Strong Buy” by “3” brokerage firms.
Analysts at Leerink said that the stock was trading down because there were 13 deaths across the study, with 10 in the low dose arm of the drug. Analyst’s mean target price for CHD is $101.23 while analysts mean recommendation is 2.80. The result is higher potency and a lower metabolic load compared to cyclosporine. The company has a Return on Assets of -126.20%. The P/S ratio is 282.60 and P/B ratio 3.27.
On 4 August, Church & Dwight Co. Inc.
ATR value of company was 0.37 and Relative Strength Index (RSI) was 28.67. Organic sales growth for the global consumer business was 4.9%. Sell-side analyst recommendations point to a short term price target of $9.77 on the company shares.
Advertisement
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) opened trading today as $2.31 and is trading in the range of 1.90-2.72 today. Over the past five trading sessions it is -16.76%; 44.69% for the month; -69.57% for the last quarter; -79.46% for the past six-months; and -86.5% for the last 12 months. Analyst’s mean target price for Lithia Motors Inc. The stock’s price moved below its 200 day moving average of $2.78. Bryan DeBoer, President and Chief Executive Officer, commented, “We are pleased to welcome DCH Ford of Thousand Oaks to our team”. We are excited to expand our relationship with Ford and further diversify our brand mix.
